Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629970778?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/20/Ai-Robot-Hand-Touching-Forex-Charts-And-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-21 02:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629970778","market":"hk","top_or_hot":-1,"title":"Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating","media":"Benzinga_recent_news","content":"<div>\n<p>That timing matters. The tape is conflicted: the Nasdaq (QQQ) is down 0.53% and the S&P 500 (SPY) is down 0.35%, while the Russell 2000 (IWM) is up 0.28%. Leadership is coming from Materials (XLB) up ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/04/51922687/candel-therapeutics-stock-soars-after-cantor-fitzgeralds-overweight-rating\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-21 02:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/04/51922687/candel-therapeutics-stock-soars-after-cantor-fitzgeralds-overweight-rating><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>That timing matters. The tape is conflicted: the Nasdaq (QQQ) is down 0.53% and the S&P 500 (SPY) is down 0.35%, while the Russell 2000 (IWM) is up 0.28%. Leadership is coming from Materials (XLB) up ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/04/51922687/candel-therapeutics-stock-soars-after-cantor-fitzgeralds-overweight-rating\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_MES","symbol_name":"微型SP500指数","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/04/51922687/candel-therapeutics-stock-soars-after-cantor-fitzgeralds-overweight-rating","article_id":"2629970778","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/20/Ai-Robot-Hand-Touching-Forex-Charts-And-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/04/51922687/candel-therapeutics-stock-soars-after-cantor-fitzgeralds-overweight-rating","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629970778","pubTimestamp":1776708480,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how narrative can outpace fundamentals.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"URTY":"ProShares UltraPro罗素2000","AVUV":"Avantis U.S. Small Cap Value ETF","SPYQ":"2倍做多SPY Quarterly ETF-Tradr","BK4539":"次新股","BK4561":"索罗斯持仓","YSPY":"GraniteShares YieldBOOST SPY ETF","SH":"做空标普500-Proshares","BK4581":"高盛持仓","VB":"小型股指数ETF-Vanguard MSCI","OEF":"标普100指数ETF-iShares","BK4217":"自存仓储房地产信托","OEX":"标普100","IWMI":"NEOS Russell 2000 High Income ETF","BK4570":"地缘局势概念股","TZA":"罗素2000指数三倍做空ETF","SSO":"2倍做多标普500ETF-ProShares","UWM":"罗素2000指数ETF两倍做多","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","TWM":"罗素2000指数两倍做空ETF","TNA":"罗素2000指数三倍做多ETF-Direxion","RSSL":"Global X Russell 2000 ETF","BK4139":"生物科技","SDS":"两倍做空标普500 ETF-ProShares","VTWO":"Vanguard Russell 2000 ETF","IVV":"标普500ETF-iShares","UPRO":"三倍做多标普500ETF-ProShares","BK4150":"赌场与赌博","TECL":"Direxion DailyTechnology Bull 3x","IWN":"罗素2000价值股指数ETF-iShares","BK4535":"淡马锡持仓","RYLD":"Global X Russell 2000 Covered Call ETF","IWF":"罗素1000成长指数ETF-iShares",".SPX":"S&P 500 Index","SRTY":"罗素2000指数三倍做空ETF-ProShares","BK4559":"巴菲特持仓","BK4504":"桥水持仓","BK4593":"纳斯达克ETF","BK4550":"红杉资本持仓","BK4588":"碎股","SPYI":"NEOS S&P 500 High Income ETF","RWM":"罗素2000指数反向ETF","CADL":"Candel Therapeutics, Inc.","SPXU":"三倍做空标普500ETF-ProShares"},"translate_title":"Cantor Fitzgerald获得跑赢大盘评级后Candel Therapeutics股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VB":0.6,".SPX":0.6,"RSSL":0.6,"VTWO":0.6,"MESmain":0.6,"OEF":0.6,"RWM":0.6,"SPYQ":0.6,"ESmain":0.6,"MNQmain":0.6,"TECL":0.6,"SPXU":0.6,"TZA":0.6,"YSPY":0.6,"IWMI":0.6,"URTY":0.6,"TWM":0.6,"AVUV":0.6,"IWF":0.6,"SDS":0.6,"IVV":0.6,"SRTY":0.6,"TNA":0.6,"SPYI":0.6,"SSO":0.6,"UPRO":0.6,"CADL":1.95,"IWN":0.6,"OEX":0.6,"RYLD":0.6,"SH":0.6,"UWM":0.6},"content_text":"That timing matters. The tape is conflicted: the Nasdaq (QQQ) is down 0.53% and the S&P 500 (SPY) is down 0.35%, while the Russell 2000 (IWM) is up 0.28%. Leadership is coming from Materials (XLB) up 0.85% and Energy (XLE) up 0.81%, and breadth is slightly negative with 5 sectors advancing and 6 declining. \nCantor Fitzgerald initiated coverage on Candel with an Overweight rating on April 20. The call lands as the stock trades near the top of its recent range, and it effectively reframes the debate from \"wait for proof\" to \"pay attention now.\" For clinical-stage companies, that shift is often the whole ballgame: expectations reset, positioning changes and the stock starts trading more on perceived optionality than on near-term numbers.\nAnd once the market starts leaning into optionality, price levels stop being trivia and start becoming triggers.\nCandel Therapeutics is pressing into new highs within its 52-week range, with price now above the prior 52-week high of $7.25, an area that often flips from \"ceiling\" to a level traders watch for follow-through.\nThe stock is trading 49.8% above its 20-day simple moving average (SMA) and 38.8% above its 100-day SMA, a setup that screams upside pressure, but also hints at how crowded the short-term move may be.\nThe relative strength index (RSI) is 75.31. That's overbought territory, which tends to pair nicely with fast, emotional buying — and not-so-nicely with sudden air pockets. Even in strong uptrends, when RSI runs this hot, the market has a habit of testing conviction with sharp pullbacks.\nKey levels are clean and, in a momentum tape, they can become self-fulfilling:\nZooming out, the stock is up 66.52% over the past 12 months, which keeps the longer-term trend constructive despite the volatility. The blemish is the death cross that occurred in March (the 50-day SMA falling below the 200-day SMA), a technical \"trend stigma\" that can hang around until longer-term averages start turning back up.\nThe stock carries a Buy Rating with an average price target of $20.00. Recent analyst moves include:\nThose numbers — $20.00, $26.00, and $22.00 — don't just sit on a spreadsheet. They become reference points for how much upside the Street is willing to underwrite, and they can influence how aggressively investors chase a move like this one.\nWhen the stock is printing new highs and the target range is still far above spot, the temptation is to treat volatility as a feature, not a bug, right up until the market decides it wants proof instead of possibility.\nOn the Benzinga Edge scorecard, the snapshot is narrow but telling:\nThe stock's trend is constructive, but not in the strongest tier versus peers.\nThe verdict is straightforward: the Benzinga Edge scorecard flags a momentum-leaning profile driven by the recent breakout attempt.\nCADL Price Action: Candel shares were up 17.27% at $7.47 at the time of publication on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro.\nImage: PeachShutterStock/Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629970778","isCrawlerRequest":true}